Bronchodilating drugs for chronic obstructive pulmonary disease: Current status and future trends

Journal of Medicinal Chemistry

Volumn 58, Issue 10, 2015, Pages 4131-4164

  Montuschi, Paolo ^a   Ciabattoni, Giovanni ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ABEDITEROL; ACLIDINIUM BROMIDE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CARMOTEROL; FORMOTEROL; GLYCOPYRRONIUM BROMIDE; INDACATEROL; IPRATROPIUM BROMIDE; LONG ACTING MUSCARINIC ANTAGONIST; MILVETEROL; MUSCARINIC ANTAGONIST BETA 2 AGONIST; MUSCARINIC RECEPTOR BLOCKING AGENT; OLODATEROL; SALBUTAMOL; SALMETEROL; SHORT ACTING MUSCARINIC ANTAGONIST; TIOTROPIUM BROMIDE; UMECLIDINIUM; UNCLASSIFIED DRUG; VILANTEROL; 5-(2-((6-(2,2-DIFLUORO-2-PHENYLETHOXY)HEXYL)AMINO)-1-HYDROXYETHYL)-8-HYDROXYQUINOLIN-2(1H)-ONE; BENZYL ALCOHOL DERIVATIVE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CHLOROBENZENE; INDAN DERIVATIVE; QUINOLONE DERIVATIVE; SCOPOLAMINE DERIVATIVE;

ABDOMINAL PAIN; AIRWAY SMOOTH MUSCLE CELL; ARTHRALGIA; BACKACHE; BLURRED VISION; BRONCHODILATATION; CARDIOVASCULAR DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONSTIPATION; COUGHING; DIABETES MELLITUS; DIARRHEA; DRUG DESIGN; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG SAFETY; HUMAN; INHALATION; LOWER RESPIRATORY TRACT INFECTION; MOLECULAR MODEL; MUSCLE SPASM; NAUSEA; NECK PAIN; NONHUMAN; OROPHARYNX PAIN; PAIN; PHARYNGITIS; REVIEW; RHINOPHARYNGITIS; RISK FACTOR; SINUSITIS; SMOOTH MUSCLE RELAXATION; STRUCTURE ACTIVITY RELATION; TACHYCARDIA; THORAX PAIN; TREMOR; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; URINE RETENTION; VERTIGO; VIRAL RESPIRATORY TRACT INFECTION; XEROSTOMIA; CHEMISTRY; DIAGNOSTIC USE; INHALATIONAL DRUG ADMINISTRATION; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

ADMINISTRATION, INHALATION; ADRENERGIC BETA-2 RECEPTOR AGONISTS; BENZYL ALCOHOLS; BRONCHODILATOR AGENTS; CHLOROBENZENES; HUMANS; INDANS; MUSCARINIC ANTAGONISTS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUINOLONES; SCOPOLAMINE DERIVATIVES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84930635941     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm5013227     Document Type: Review

References (181)

1. Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD), 2014. Available from www.goldcopd.org.
2. Montuschi, P. Drugs for chronic obstructive pulmonary disease Curr. Med. Chem. 2013, 20, 1461-1463
3. Montuschi, P.; Macagno, F.; Valente, S.; Fuso, L. Inhaled muscarinic acetylcholine receptor antagonists for treatment of COPD Curr. Med. Chem. 2013, 20, 1464-1476
4. Fuso, L.; Mores, N.; Valente, S.; Malerba, M.; Montuschi, P. Long-acting beta-agonists and their association with inhaled corticosteroids in COPD Curr. Med. Chem. 2013, 20, 1477-1495
5. Woods, J. A.; Nealy, K. L.; Barrons, R. W. Aclidinium bromide: an alternative long-acting inhaled anticholinergic in the management of chronic obstructive pulmonary disease Ann. Pharmacother. 2013, 47, 1017-1028
6. Carter, N. J. Inhaled glycopyrronium bromide: a review of its use in patients with moderate to severe chronic obstructive pulmonary disease Drugs 2013, 73, 741-753
7. Scott, L. J.; Hair, P. Umeclidinium/vilanterol: first global approval Drugs 2014, 74, 389-395
8. Moen, M. D. Indacaterol: in chronic obstructive pulmonary disease Drugs 2010, 70, 2269-2280
9. Belmonte, K. E. Cholinergic pathways in the lungs and anticholinergic therapy for chronic obstructive pulmonary disease Proc. Am. Thorac. Soc. 2005, 2, 297-304
10. Montuschi, P.; Malerba, M.; Santini, G.; Miravitlles, M. Pharmacological treatment of chronic obstructive pulmonary disease: from evidence-based medicine to phenotyping Drug Discovery Today 2014, 19, 1928-1935
11. Roffel, A. F.; Meurs, H.; Zaagsma, J. Identification, localization and function of muscarinic receptor subtypes in the airways. In Muscarinic Receptors in Airways Diseases; Zagsma, J.; Meurs, H.; Roffel, A. F., Ed.; Birkhauser Verlag: Basel, Switzerland, 2001; pp 63-85.
12. Brown, S. M.; Koarai, A.; Sturton, R. G.; Nicholson, A. G.; Barnes, P. J.; Donnelly, L. E. A role for M2 and M3 muscarinic receptors in the contraction of rat and human small airways Eur. J. Pharmacol. 2013, 702, 109-115
13. Johnson, M. The β-adrenoceptor Am. J. Respir. Crit. Care Med. 1998, 158, S146-S153
14. Cave, A. C.; Hurst, M. M. The use of long acting β2-agonists, alone or in combination with inhaled corticosteroids, in chronic obstructive pulmonary disease (COPD): a risk-benefit analysis Pharmacol. Ther. 2011, 130, 114-143
15. Procopiou, P. A.; Barrett, V. J.; Bevan, N. J.; Biggadike, K.; Butchers, P. R.; Coe, D. M.; Conroy, R.; Edney, D. D.; Field, R. N.; Ford, A. J.; Guntrip, S. B.; Looker, B. E.; McLay, I. M.; Monteith, M. J.; Morrison, V. S.; Mutch, P. J.; Richards, S. A.; Sasse, R.; Smith, C. E. Synthesis and structure-activity relationships of long-acting beta2 adrenergic receptor agonists incorporating arylsulfonamide groups J. Med. Chem. 2009, 52, 2280-2288
16. Baur, F.; Beattie, D.; Beer, D.; Bentley, D.; Bradley, M.; Bruce, I.; Charlton, S. J.; Cuenoud, B.; Ernst, R.; Fairhurst, R. A.; Faller, B.; Farr, D.; Keller, T.; Fozard, J. R.; Fullerton, J.; Garman, S.; Hatto, J.; Hayden, C.; He, H.; Howes, C.; Janus, D.; Jiang, Z.; Lewis, C.; Loeuillet-Ritzler, F.; Moser, H.; Reilly, J.; Steward, A.; Sykes, D.; Tedaldi, L.; Trifilieff, A.; Tweed, M.; Watson, S.; Wissler, E.; Wyss, D. The identification of indacaterol as an ultra long-acting inhaled beta2-adrenoceptor agonist J. Med. Chem. 2010, 53, 3675-3684
17. Szczuka, A.; Wennerberg, M.; Packeu, A.; Vauquelin, G. Molecular mechanisms for the persistent bronchodilatory effect of the beta2-adrenoceptor agonist salmeterol Br. J. Pharmacol. 2009, 158, 183-194
18. Rhodes, D. G.; Newton, R.; Butler, R.; Herbette, L. Equilibrium and kinetic studies of the interactions of salmeterol with membrane bilayers Mol. Pharmacol. 1992, 42, 596-602
19. Johnson, M. Beta2-adrenoceptors: mechanisms of action of beta2-agonists Paediatr. Respir. Rev. 2001, 2, 57-62
20. Coleman, R. A.; Johnson, M.; Nials, A. T.; Vardey, C. J. Exosites: their current status, and their relevance to the duration of action of long-acting beta2-adrenoceptor agonists Trends Pharmacol. Sci. 1996, 17, 324-330
21. Austin, R. P.; Barton, P.; Bonnert, R. V.; Brown, R. C.; Cage, P. A.; Cheshire, D. R.; Davis, A. M.; Dougall, I. G.; Ince, F.; Pairaudeau, G.; Young, A. QSAR and the rational design of long-acting dual D2-receptor/beta2-adrenoceptor agonists J. Med. Chem. 2003, 46, 3210-3220
22. Glossop, P. A.; Watson, C. A.; Price, D. A.; Bunnage, M. E.; Middleton, D. S.; Wood, A.; James, K.; Roberts, D.; Strang, R. S.; Yeadon, M.; Perros-Huguet, C.; Clarke, N. P.; Trevethick, M. A.; Machin, I.; Stuart, E. F.; Evans, S. M.; Harrison, A. C.; Fairman, D. A.; Agoram, B.; Burrows, J. L.; Feeder, N.; Fulton, C. K.; Dillon, B. R.; Entwistle, D. A.; Spence, F. J. Inhalation by design: novel tertiary amine muscarinic M3 receptor antagonists with slow off-rate binding kinetics for inhaled once-daily treatment of chronic obstructive pulmonary disease J. Med. Chem. 2011, 54, 6888-6904
23. Brown, J. H.; Taylor, P. Muscarinic receptor agonists and antagonists. In Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9 th ed.; Hardman, J. G.; Limbird, L. E.; Molinoff, P. B.; Ruddon, R. W.; Gilman, A. G., Eds.; McGraw-Hill: New York, 1996; pp 141-160.
24. Gordon, R. K.; Breuer, E.; Padilla, F. N.; Smejkal, R. M.; Chaing, P. K. Distance geometry of α-substituted 2,2-diphenylpropionate antimuscarinics Mol. Pharmacol. 1989, 36, 766-772
25. Tautermann, C. S.; Kiechle, T.; Seeliger, D.; Diehl, S.; Wex, E.; Banholzer, R.; Gantner, F.; Pieper, M. P.; Casarosa, P. Molecular basis for the long duration of action and kinetic selectivity of tiotropium for the muscarinic M3 receptor J. Med. Chem. 2013, 56, 8746-8756
26. Lainé, D. I.; Wan, Z.; Yan, H.; Zhu, C.; Xie, H.; Fu, W.; Busch-Petersen, J.; Neipp, C.; Davis, R.; Widdowson, K. L.; Blaney, F. E.; Foley, J.; Bacon, A. M.; Webb, E. F.; Luttmann, M. A.; Burman, M.; Sarau, H. M.; Salmon, M.; Palovich, M. R.; Belmonte, K. Design, synthesis, and structure-activity relationship of tropane muscarinic acetylcholine receptor antagonists J. Med. Chem. 2009, 52, 5241-5252
27. Stocks, M. J.; Alcaraz, L.; Bailey, A.; Bowers, K.; Donald, D.; Edwards, H.; Hunt, F.; Kindon, N.; Pairaudeau, G.; Theaker, J.; Warner, D. J. The discovery of new spirocyclic muscarinic M3 antagonists Bioorg. Med. Chem. Lett. 2010, 20, 7458-7461
28. Lainé, D. I.; McCleland, B.; Thomas, S.; Neipp, C.; Underwood, B.; Dufour, J.; Widdowson, K. L.; Palovich, M. R.; Blaney, F. E.; Foley, J. J.; Webb, E. F.; Luttmann, M. A.; Burman, M.; Belmonte, K.; Salmon, M. Discovery of novel 1-azoniabicyclo[2.2.2]octane muscarinic acetylcholine receptor antagonists J. Med. Chem. 2009, 52, 2493-2505
29. Kiesewetter, D. O.; Silverton, J. V.; Eckelman, W. C. Syntheses and biological properties of chiral fluoroalkyl quinuclidinyl benzilates J. Med. Chem. 1995, 38, 1711-1719
30. Noronha-Blob, L.; Sturm, B.; Lowe, V. Stereoselective antimuscarinic effects of 3-quinuclidinyl atrolactate and 3-quinuclidinyl xanthene-9-carboxylate Eur. J. Pharmacol. 1992, 211, 97-103
31. Prat, M.; Fernández, D.; Buil, M. A.; Crespo, M. I.; Casals, G.; Ferrer, M.; Tort, L.; Castro, J.; Monleón, J. M.; Gavaldà, A.; Miralpeix, M.; Ramos, I.; Doménech, T.; Vilella, D.; Antón, F.; Huerta, J. M.; Espinosa, S.; López, M.; Sentellas, S.; González, M.; Albertí, J.; Segarra, V.; Cárdenas, A.; Beleta, J.; Ryder, H. Discovery of novel quaternary ammonium derivatives of (3 R)-quinuclidinol esters as potent and long-acting muscarinic antagonists with potential for minimal systemic exposure after inhaled administration: identification of (3 R)-3-{[hydroxy(di-2-thienyl)acetyl]oxy}-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2] octane bromide (aclidinium bromide) J. Med. Chem. 2009, 52, 5076-5092
32. Martel, A. M.; Rabasseda, X.; Castañer, J. Revatropate. Bronchodilator muscarinic M3 antagonist Drugs Future 1997, 22, 135-137
33. Tropsha, A. E.; Nizhnii, S. V.; Iaguzhinskii, L. S. Structure-activity relationship in the series of muscarinic acetylcholine receptor antagonists: four types of antagonist-receptor binding Bioorg. Khim. 1985, 11, 1402-1416
34. Gavaldà, A.; Miralpeix, M.; Ramos, I.; Otal, R.; Carreño, C.; Viñals, M.; Doménech, T.; Carcasona, C.; Reyes, B.; Vilella, D.; Gras, J.; Cortijo, J.; Morcillo, E.; Llenas, J.; Ryder, H.; Beleta, J. Characterization of aclidinium bromide, a novel inhaled muscarinic antagonist, with long duration of action and a favorable pharmacological profile J. Pharmacol. Exp. Ther. 2009, 331, 740-751
35. Beier, J.; Kirsten, A. M.; Mróz, R.; Segarra, R.; Chuecos, F.; Caracta, C.; Gil, E. G. Efficacy and safety of aclidinium bromide compared with placebo and tiotropium in patients with moderate-to-severe chronic obstructive pulmonary disease: results from a 6-week, randomized, controlled phase IIIb study COPD 2013, 10, 511-522
36. Milara, J.; Serrano, A.; Peiró, T.; Gavaldà, A.; Miralpeix, M.; Morcillo, E. J.; Cortijo, J. Aclidinium inhibits human lung fibroblast to myofibroblast transition Thorax 2012, 67, 229-237
37. Milara, J.; Serrano, A.; Peiró, T.; Artigues, E.; Gavaldà, A.; Miralpeix, M.; Morcillo, E. J.; Cortijo, J. Aclidinium inhibits cigarette smoke-induced lung fibroblast-to-myofibroblast transition Eur. Respir. J. 2013, 41, 1264-1274
38. Domínguez-Fandos, D.; Ferrer, E.; Puig-Pey, R.; Carreño, C.; Prats, N.; Aparici, M.; Musri, M. M.; Gavaldà, A.; Peinado, V. I.; Miralpeix, M.; Barberà, J. A. Effects of aclidinium bromide in a cigarette smoke-exposed guinea pig model of chronic obstructive pulmonary disease Am. J. Respir. Cell Mol. Biol. 2014, 50, 337-346
39. Lainé, D. I.; Yan, H.; Xie, H.; Davis, R. S.; Dufour, J.; Widdowson, K. L.; Palovich, M. R.; Wan, Z.; Foley, J. J.; Schmidt, D. B.; Hunsberger, G. E.; Burman, M.; Bacon, A. M.; Webb, E. F.; Luttmann, M. A.; Salmon, M.; Sarau, H. M.; Umbrecht, S. T.; Landis, P. S.; Peck, B. J.; Busch-Petersen, J. Design, synthesis and structure-activity relationship of N-substituted tropane muscarinic acetylcholine receptor antagonists Bioorg. Med. Chem. Lett. 2012, 22, 3366-3369
40. Nagashima, S.; Matsushima, Y.; Hamaguchi, H.; Nagata, H.; Kontani, T.; Moritomo, A.; Koshika, T.; Takeuchi, M. Novel quinuclidinyl heteroarylcarbamate derivatives as muscarinic receptor antagonists Bioorg. Med. Chem. 2014, 22, 3478-3487
41. Peretto, I.; Forlani, R.; Fossati, C.; Giardina, G. A.; Giardini, A.; Guala, M.; La Porta, E.; Petrillo, P.; Radaelli, S.; Radice, L.; Raveglia, L. F.; Santoro, E.; Scudellaro, R.; Scarpitta, F.; Bigogno, C.; Misiano, P.; Dondio, G. M.; Rizzi, A.; Armani, E.; Amari, G.; Civelli, M.; Villetti, G.; Patacchini, R.; Bergamaschi, M.; Delcanale, M.; Salcedo, C.; Fernández, A. G.; Imbimbo, B. P. Discovery of diaryl imidazolidin-2-one derivatives, a novel class of muscarinic M3 selective antagonists (Part 1) J. Med. Chem. 2007, 50, 1571-1583
42. Peretto, I.; Fossati, C.; Giardina, G. A.; Giardini, A.; Guala, M.; La Porta, E.; Petrillo, P.; Radaelli, S.; Radice, L.; Raveglia, L. F.; Santoro, E.; Scudellaro, R.; Scarpitta, F.; Cerri, A.; Menegon, S.; Dondio, G. M.; Rizzi, A.; Armani, E.; Amari, G.; Civelli, M.; Villetti, G.; Patacchini, R.; Bergamaschi, M.; Bassani, F.; Delcanale, M.; Imbimbo, B. P. Discovery of diaryl imidazolidin-2-one derivatives, a novel class of muscarinic M3 selective antagonists (part 2) J. Med. Chem. 2007, 50, 1693-1697
43. Villetti, G.; Pastore, F.; Bergamaschi, M.; Bassani, F.; Bolzoni, P. T.; Battipaglia, L.; Amari, G.; Rizzi, A.; Delcanale, M.; Volta, R.; Cenacchi, V.; Cacciani, F.; Zaniboni, M.; Berti, F.; Rossoni, G.; Harrison, S.; Petrillo, P.; Santoro, E.; Scudellaro, R.; Mannini, F.; Geppetti, P. A.; Razzetti, R.; Patacchini, R.; Civelli, M. Bronchodilator activity of (3 R)-3-[[[(3-fluorophenyl)[(3,4,5-trifluorophenyl)methyl]amino]carbonyl]oxy]-1-[2-oxo-2-(2-thienyl)ethyl]-1-azoniabicyclo[2.2.2]octane bromide (CHF5407), a potent, long-acting, and selective muscarinic M3 receptor antagonist J. Pharmacol. Exp. Ther. 2010, 335, 622-635
44. Herbette, L. G. Membrane pathways for drug/ion channel interactions: molecular basis for pharmacokinetic properties Drug Dev. Res. 1994, 33, 214-222
45. Brown, A. D.; Bunnage, M. E.; Glossop, P. A.; James, K.; Jones, R.; Lane, C. A.; Lewthwaite, R. A.; Mantell, S.; Perros-Huguet, C.; Price, D. A.; Trevethick, M.; Webster, R. The discovery of long acting β2-adrenoreceptor agonists Bioorg. Med. Chem. Lett. 2007, 17, 4012-4015
46. Blaney, F. E.; Tennant, M. Computational tools and results in the construction of G protein-coupled receptor models. In Membrane Protein Models; Findlay, J. B. C., Ed.; Bios Scientific Publishers, Ltd.: Oxford, U.K., 1996; pp 161-176.
47. Isogaya, M.; Yamagiwa, Y.; Fujita, S.; Sugimoto, Y.; Nagao, T.; Kurose, H. Identification of a key amino acid of the β2-adrenergic receptor for high affinity binding of salmeterol Mol. Pharmacol. 1998, 54, 616-622
48. Isogaya, M.; Sugimoto, Y.; Tanimura, R.; Tanaka, R.; Kikkawa, H.; Nagao, T.; Kurose, H. Binding pockets of the β1 and β2 adrenergic receptors for subtype-selective agonists Mol. Pharmacol. 1999, 56, 875-885
49. Green, S. A.; Spasoff, A. P.; Coleman, R. R.; Johnson, M.; Liggett, S. B. Sustained activation of a G-protein-coupled receptor via "anchored" agonist binding. Molecular localization of the salmeterol exosite within the β2-adrenergic receptor J. Biol. Chem. 1996, 271, 24029-24035
50. Prashad, M.; Hu, B.; Har, D.; Repic, O.; Blacklock, T. J. An efficient and economical synthesis of 5,6-diethyl-2,3-dihydro-1 H -inden-2-amine hydrochloride Org. Process Res. Dev. 2006, 10, 135-141
51. Beattie, D.; Beer, D.; Bradley, M. E.; Bruce, I.; Charlton, S. J.; Cuenoud, B. M.; Fairhurst, R. A.; Farr, D.; Fozard, J. R.; Janus, D.; Rosethorne, E. M.; Sandham, D. A.; Sykes, D. A.; Trifilieff, A.; Turner, K. L.; Wissler, E. An investigation into the structure-activity relationships associated with the systematic modification of the β2-adrenoceptor agonist indacaterol Bioorg. Med. Chem. Lett. 2012, 22, 6280-6285
52. Rosenbaum, D. M.; Cherezov, V.; Hanson, M. A.; Rasmussen, S. G. F.; Thian, F. S.; Kobilka, T. S.; Choi, H.-J.; Yao, X.-J.; Weis, W. I.; Stevens, R. C.; Kobilka, B. K. GPCR engineering yields high-resolution structural insights into β2-adrenergic receptor function Science 2007, 318, 1266-1273
53. Rasmussen, S. G. F.; Choi, H.-J.; Rosenbaum, D. M.; Kobilka, T. S.; Thian, F. S.; Edwards, P. C.; Burghammer, M.; Ratnala, V. R. P.; Sanishvili, R.; Fischetti, R. F.; Schertler, G. F. X.; Weis, W. I.; Kobilka, B. K. Crystal structure of the human β2 adrenergic G-protein-coupled receptor Nature 2007, 450, 383-388
54. Procopiou, P. A.; Barrett, V. J.; Bevan, N. J.; Biggadike, K.; Box, P. C.; Butchers, P. R.; Coe, D. M.; Conroy, R.; Emmons, A.; Ford, A. J.; Holmes, D. S.; Horsley, H.; Kerr, F.; Li-Kwai-Cheung, A. M.; Looker, B. E.; Mann, I. S.; McLay, I. M.; Morrison, V. S.; Mutch, P. J.; Smith, C. E.; Tomlin, P. Synthesis and structure-activity relationships of long-acting beta2 adrenergic receptor agonists incorporating metabolic inactivation: an antedrug approach J. Med. Chem. 2010, 53, 4522-4530
55. Kempsford, R.; Norris, V.; Siederer, S. Vilanterol trifenatate, a novel inhaled long-acting β2 adrenoceptor agonist, is well tolerated in healthy subjects and demonstrates prolonged bronchodilation in subjects with asthma and COPD Pulm. Pharmacol. Ther. 2013, 26, 256-264
56. Slack, R. J.; Barrett, V. J.; Morrison, V. S.; Sturton, R. G.; Emmons, A. J.; Ford, A. J.; Knowles, R. G. In vitro pharmacological characterization of vilanterol, a novel long-acting β2-adrenoceptor agonist with 24-hour duration of action J. Pharmacol. Exp. Ther. 2013, 344, 218-230
57. Brown, A. D.; Bunnage, M. E.; Glossop, P. A.; James, K.; Jones, R.; Lane, C. A.; Lewthwaite, R. A.; Mantell, S.; Perros-Huguet, C.; Price, D. A.; Trevethick, M.; Webster, R. The discovery of adamantyl-derived, inhaled, long acting beta2-adrenoreceptor agonists Bioorg. Med. Chem. Lett. 2008, 18, 1280-1283
58. Brown, A. D.; Bunnage, M. E.; Glossop, P. A.; Holbrook, M.; Jones, R. D.; Lane, C. A.; Lewthwaite, R. A.; Mantell, S.; Perros-Huguet, C.; Price, D. A.; Webster, R. The discovery of indole-derived long acting beta2-adrenoceptor agonists for the treatment of asthma and COPD Bioorg. Med. Chem. Lett. 2007, 17, 6188-6191
59. Glossop, P. A.; Lane, C. A.; Price, D. A.; Bunnage, M. E.; Lewthwaite, R. A.; James, K.; Brown, A. D.; Yeadon, M.; Perros-Huguet, C.; Trevethick, M. A.; Clarke, N. P.; Webster, R.; Jones, R. M.; Burrows, J. L.; Feeder, N.; Taylor, S. C.; Spence, F. J. Inhalation by design: novel ultra-long-acting β2-adrenoreceptor agonists for inhaled once-daily treatment of asthma and chronic obstructive pulmonary disease that utilize a sulfonamide agonist headgroup J. Med. Chem. 2010, 53, 6640-6652
60. Bouyssou, T.; Rudolf, K.; Hoenke, C.; Lustenberger, P.; Schnapp, A.; Konetzki, I. Studies towards topical selective β2-adrenoceptor agonists with a long duration of action Bioorg. Med. Chem. Lett. 2009, 19, 5237-5240
61. Hoenke, C.; Bouyssou, T.; Tautermann, C. S.; Rudolf, K.; Schnapp, A.; Konetzki, I. Use of 5-hydroxy-4 H -benzo[1,4]oxazin-3-ones as β2-adrenoceptor agonists Bioorg. Med. Chem. Lett. 2009, 19, 6640-6644
62. Bouyssou, T.; Hoenke, C.; Rudolf, K.; Lustenberger, P.; Pestel, S.; Sieger, P.; Lotz, R.; Heine, C.; Buttner, F. H.; Schnapp, A.; Konetzki, I. Discovery of olodaterol, a novel inhaled β2-adrenoceptor agonist with a 24 h bronchodilatory efficacy Bioorg. Med. Chem. Lett. 2010, 20, 1410-1414
63. Gibb, A.; Yang, L. P. Olodaterol: first global approval Drugs 2013, 73, 1841-1846
64. Connolly, S.; Alcaraz, L.; Bailey, A.; Cadogan, E.; Christie, J.; Cook, A. R.; Fisher, A. J.; Hill, S.; Humphries, A.; Ingall, A. H.; Kane, Z.; Paine, S.; Pairaudeau, G.; Stocks, M. J.; Young, A. Design-driven LO: the discovery of new ultra long acting dibasic β2-adrenoceptor agonists Bioorg. Med. Chem. Lett. 2011, 21, 4612-4616
65. Alcaraz, L.; Bailey, A.; Cadogan, E.; Connolly, S.; Jewell, R.; Jordan, S.; Kindon, N.; Lister, A.; Lawson, M.; Mullen, A.; Dainty, I.; Nicholls, D.; Paine, S.; Pairaudeau, G.; Stocks, M. J.; Thorne, P.; Young, A. From libraries to candidate: the discovery of new ultra long-acting dibasic β2-adrenoceptor agonists Bioorg. Med. Chem. Lett. 2012, 22, 689-695
66. Beattie, D.; Bradley, M.; Brearley, A.; Charlton, S. J.; Cuenoud, B. M.; Fairhurst, R. A.; Gedeck, P.; Gosling, M.; Janus, D.; Jones, D.; Lewis, C.; McCarthy, C.; Oakman, H.; Stringer, R.; Taylor, R. J.; Tuffnell, A. A physical properties based approach for the exploration of a 4-hydroxybenzothiazolone series of beta2-adrenoceptor agonists as inhaled long-acting bronchodilators Bioorg. Med. Chem. Lett. 2010, 20, 5302-5307
67. Sin, D. D.; Tu, J. V. Lack of association between ipratropium bromide and mortality in elderly patients with chronic obstructive airway disease Thorax 2000, 55, 194-197
68. Anthonisen, N. R.; Connett, J. E.; Kiley, J. P.; Altose, M. D.; Bailey, W. C.; Buist, A. S.; Conway, W. A., Jr.; Enright, P. L.; Kanner, R. E.; O'Hara, P.; Owens, G. R.; Scanlon, P. D.; Tashkin, D. P.; Wise, R. A. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study JAMA, J. Am. Med. Assoc. 1994, 272, 1497-1505
69. Tashkin, D. P.; Ashutosh, K.; Bleecker, E. R.; Britt, E. J.; Cugell, D. W.; Cummiskey, J. M.; DeLorenzo, L.; Gilman, M. J.; Gross, G. N.; Gross, N. J.; Kotch, A.; Lakshminarayan, S.; Maguire, G.; Miller, M.; Plummer, A.; Renzetti, A.; Sackner, M. A.; Skorodin, M. S.; Wanner, A.; Watanabe, S. Comparison of the anticholinergic bronchodilator ipratropium bromide with metaproterenol in chronic obstructive pulmonary disease. A 90-day multi-center study Am. J. Med. 1986, 81, 81-90
70. Chervinsky, P. Concomitant bronchodilator therapy and ipratropium bromide. A clinical review Am. J. Med. 1986, 81, 67-73
71. Wadbo, M.; Lofdahl, C. G.; Larsson, K.; Skoogh, B. E.; Tornling, G.; Arwestrom, E.; Bengtsson, T.; Strom, K. Effects of formoterol and ipratropium bromide in COPD: a 3-month placebo-controlled study Eur. Respir. J. 2002, 20, 1138-1146
72. Colice, G. L. Nebulized bronchodilators for outpatient management of stable chronic obstructive pulmonary disease Am. J. Med. 1996, 100, 11S-18S
73. COMBIVENT Inhalation Aerosol Study Group In chronic obstructive pulmonary disease, a combination of ipratropium and albuterol is more effective than either agent alone. An 85-day multicenter trial Chest 1994, 105, 1411-1419
74. Gross, N.; Tashkin, D.; Miller, R.; Oren, J.; Coleman, W.; Linberg, S. Inhalation by nebulization of albuterol-ipratropium combination (Dey combination) is superior to either agent alone in the treatment of chronic obstructive pulmonary disease. Dey Combination Solution Study Group Respiration 1998, 65, 354-362
75. Friedman, M.; Serby, C. W.; Menjoge, S. S.; Wilson, J. D.; Hilleman, D. E.; Witek, T. J., Jr. Pharmacoeconomic evaluation of a combination of ipratropium plus albuterol compared with ipratropium alone and albuterol alone in COPD Chest 1999, 115, 635-641
76. Disse, B.; Speck, G. A.; Rominger, K. L.; Witek, T. J., Jr.; Hammer, R. Tiotropium (Spiriva): mechanistical considerations and clinical profile in obstructive lung disease Life Sci. 1999, 64, 457-464
77. Calverley, P. M. A.; Lee, A.; Towse, L.; van Noord, J.; Witek, T. J.; Kelsen, S. Effect of tiotropium bromide on circadian variation in airflow limitation in chronic obstructive pulmonary disease Thorax 2003, 58, 855-860
78. Barr, R. G.; Bourbeau, J.; Camargo, C. A.; Ram, F. S. Tiotropium for stable chronic obstructive pulmonary disease: a meta-analysis Thorax 2006, 61, 854-862
79. Casaburi, R.; Briggs, D. D., Jr.; Donohue, J. F.; Serby, C. W.; Menjoge, S. S.; Witek, T. J., Jr. The spirometric efficacy of once-daily dosing with tiotropium in stable COPD: a 13-week multicenter trial. The US Tiotropium Study Group Chest 2000, 118, 1294-1302
80. van Noord, J. A.; Bantje, T. A.; Eland, M. E.; Korducki, L.; Cornelissen, P. J. A randomised controlled comparison of tiotropium and ipratropium in the treatment of chronic obstructive pulmonary disease. The Dutch Tiotropium Study Group Thorax 2000, 55, 289-294
81. Niewoehner, D. E.; Rice, K.; Cote, C.; Paulson, D.; Cooper, J. A., Jr.; Korducki, L.; Cassino, C.; Kesten, S. Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator: a randomized trial Ann. Intern. Med. 2005, 143, 317-326
82. Casaburi, R.; Mahler, D. A.; Jones, P. W.; Wanner, A.; San, P. G.; ZuWallack, R. L.; Menjoge, S. S.; Serby, C. W.; Witek, T., Jr. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease Eur. Respir. J. 2002, 19, 217-224
83. O'Donnell, D. E.; Flüge, T.; Gerken, F.; Hamilton, A.; Webb, K.; Aguilaniu, B.; Make, B.; Magnussen, H. Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD Eur. Respir. J. 2004, 23, 832-840
84. McNicholas, W. T.; Calverley, P. M.; Lee, A.; Edwards, J. C.; Tiotropium Sleep Study in COPD Investigators. Long-acting inhaled anticholinergic therapy improves sleeping oxygen saturation in COPD Eur. Respir. J. 2004, 23, 825-831
85. Tashkin, D.; Kesten, S. Long-term treatment benefits with tiotropium in COPD patients with and without short-term bronchodilator responses Chest 2003, 123, 1441-1449
86. Tashkin, D. P.; Celli, B.; Senn, S.; Burkhart, D.; Kesten, S.; Menjoge, S.; Decramer, M.; UPLIFT Study Investigators. A four-year trial of tiotropium in chronic obstructive pulmonary disease N. Engl. J. Med. 2008, 359, 1543-1554
87. Decramer, M.; Celli, B.; Kesten, S.; Lystig, T.; Mehra, S.; Tashkin, D. P.; UPLIFT Investigators. Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial Lancet 2009, 374, 1171-1178
88. Tashkin, D. P.; Celli, B.; Kesten, S.; Lystig, T.; Mehra, S.; Decramer, M. Long-term efficacy of tiotropium in relation to smoking status in the UPLIFT trial Eur. Respir. J. 2010, 35, 287-294
89. Celli, B.; Decramer, M.; Kesten, S.; Liu, D.; Mehra, S.; Tashkin, D. P.; UPLIFT Study Investigators. Mortality in the 4-year trial of tiotropium (UPLIFT) in patients with chronic obstructive pulmonary disease Am. J. Respir. Crit. Care Med. 2009, 180, 948-955
90. Dusser, D.; Bravo, M.-L.; Iacono, P. The effect of tiotropium on exacerbations and airflow in patients with COPD Eur. Respir. J. 2006, 27, 547-555
91. Powrie, D. J.; Wilkinson, T. M. A.; Donaldson, G. C.; Jones, P.; Scrine, K.; Viel, K.; Kesten, S.; Wedzicha, J. A. Effect of tiotropium on sputum and serum inflammatory markers and exacerbations in COPD Eur. Respir. J. 2007, 30, 472-478
92. Rodrigo, G. J.; Nannini, L. J. Tiotropium for the treatment of stable chronic obstructive pulmonary disease: a systematic review with meta-analysis Pulm. Pharmacol. Ther. 2007, 20, 495-502
93. Vogelmeier, C.; Hederer, B.; Glaab, T.; Schmidt, H.; Rutten-van Mölken, M. P.; Beeh, K. M.; Rabe, K. F.; Fabbri, L. M.; POET-COPD Investigators. Tiotropium versus salmeterol for the prevention of exacerbations of COPD N. Engl. J. Med. 2011, 364, 1093-1103
94. Wedzicha, J. A.; Calverley, P. M.; Seemungal, T. A.; Hagan, G.; Ansari, Z.; Stockley, R. A.; INSPIRE Investigators. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide Am. J. Respir. Crit. Care Med. 2008, 177, 19-26
95. Chan, C. K. N.; Maltais, R.; Sigouin, C.; Haddon, J. M.; Ford, G. T.; SAFE Study Group. A randomized controlled trial to assess the efficacy of tiotropium in Canadian patients with chronic obstructive pulmonary disease Can. Respir. J. 2007, 14, 465-472
96. Tonnel, A. B.; Perez, T.; Grosbois, J. M.; Verkindre, C.; Bravo, M. L.; Brun, M.; TIPHON Study Group. Effect of tiotropium on health-related quality of life as a primary efficacy endpoint in COPD Int. J. Chronic Obstruct. Pulm. Dis. 2008, 3, 301-310
97. Verkindre, C.; Bart, F.; Aguilaniu, B.; Fortin, F.; Guérin, J. C.; Le Merre, C.; Iacono, P.; Huchon, G. The effect of tiotropium on hyperinflation and exercise capacity in chronic obstructive pulmonary disease Respiration 2006, 73, 420-427
98. Brusasco, V.; Hodder, R.; Miravitlles, M.; Korducki, L.; Towse, L.; Kesten, S. Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD Thorax 2003, 58, 399-404
99. Tashkin, D. P.; Cooper, C. B. The role of long-acting bronchodilators in the management of stable COPD Chest 2004, 125, 249-259
100. Sykes, D. A.; Dowling, M. R.; Leighton-Davies, J.; Kent, T. C.; Fawcett, L.; Renard, E.; Trifilieff, A.; Charlton, S. J. The influence of receptor kinetics on the onset and duration of action and the therapeutic index of NVA237 and tiotropium J. Pharmacol. Exp. Ther. 2012, 343, 520-528
101. Verkindre, C.; Fukuchi, Y.; Flémale, A.; Takeda, A.; Overend, T.; Prasad, N.; Dolker, M. Sustained 24-h efficacy of NVA237, a once-daily long-acting muscarinic antagonist, in COPD patients Respir. Med. 2010, 104, 1482-1489
102. Casarosa, P.; Bouyssou, T.; Germeyer, S.; Schnapp, A.; Gantner, F.; Pieper, M. Preclinical evaluation of long-acting muscarinic antagonists: comparison of tiotropium and investigational drugs J. Pharmacol. Exp. Ther. 2009, 330, 660-668
103. Villetti, G.; Bergamaschi, M.; Bassani, F.; Bolzoni, P. T.; Harrison, S.; Gigli, P. M.; Janni, A.; Geppetti, P.; Civelli, M.; Patacchini, R. Pharmacological assessment of the duration of action of glycopyrrolate vs tiotropium and ipratropium in guinea-pig and human airways Br. J. Pharmacol. 2006, 148, 291-298
104. Fogarty, C.; Hattersley, H.; Di Scala, L.; Drollmann, A. Bronchodilatory effects of NVA237, a once daily long-acting muscarinic antagonist, in COPD patients Respir. Med. 2011, 105, 337-342
105. Vauquelin, G.; Charlton, S. J. Long-lasting target binding and rebinding as mechanisms to prolong in vivo drug action Br. J. Pharmacol. 2010, 161, 488-508
106. Vogelmeier, C.; Banerji, D. NVA237, a long-acting muscarinic antagonist, as an emerging therapy for chronic obstructive pulmonary disease Ther. Adv. Respir. Dis. 2011, 5, 163-173
107. D'Urzo, A.; Ferguson, G. T.; van Noord, J. A.; Hirata, K.; Martin, C.; Horton, R.; Lu, Y.; Banerji, D.; Overend, T. Efficacy and safety of once-daily NVA237 in patients with moderate-to-severe COPD: the GLOW1 trial Respir. Res. 2011, 12, 156
108. Kerwin, E.; Hébert, J.; Gallagher, N.; Martin, C.; Overend, T.; Alagappan, V. K.; Lu, Y.; Banerji, D. Efficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 study Eur. Respir. J. 2012, 40, 1106-1114
109. Beeh, K. M.; Singh, D.; Di Scala, L.; Drollmann, A. Once-daily NVA237 improves exercise tolerance from the first dose in patients with COPD: the GLOW3 trial Int. J. Chronic Obstruct. Pulm. Dis. 2012, 7, 503-513
110. Chapman, K. R.; Beeh, K. M.; Beier, J.; Bateman, E. D.; D'Urzo, A.; Nutbrown, R.; Henley, M.; Chen, H.; Overend, T.; D'Andrea, P. A blinded evaluation of the efficacy and safety of glycopyrronium, a once-daily long-acting muscarinic antagonist, versus tiotropium, in patients with COPD: the GLOW5 study BMC Pulm. Med. 2014, 14, 4
111. Jansat, J. M.; Lamarca, R.; Garcia Gil, E.; Ferrer, P. Safety and pharmacokinetics of single doses of aclidinium bromide, a novel long-acting, inhaled antimuscarinic, in healthy subjects Int. J. Clin. Pharmacol. Ther. 2009, 47, 460-468
112. Jones, P. W.; Rennard, S. I.; Agusti, A.; Chanez, P.; Magnussen, H.; Fabbri, L.; Donohue, J. F.; Bateman, E. D.; Gross, N. J.; Lamarca, R.; Caracta, C.; Garcia-Gil, E. Efficacy and safety of once-daily aclidinium in chronic obstructive pulmonary disease Respir. Res. 2011, 12, 55
113. Maltais, F.; Celli, B.; Casaburi, R.; Porszasz, J.; Jarreta, D.; Seoane, B.; Caracta, C. Aclidinium bromide improves exercise endurance and lung hyperinflation in patients with moderate to severe COPD Respir. Med. 2011, 105, 580-587
114. Singh, S.; Loke, Y. K.; Furberg, C. D. Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis JAMA, J. Am. Med. Assoc. 2008, 300, 1439-1450
115. Ogale, S. S.; Lee, T. A.; Au, D. H.; Boudreau, D. M.; Sullivan, S. D. Cardiovascular events associated with ipratropium bromide in COPD Chest 2010, 137, 13-19
116. Celli, B.; Decramer, M.; Leimer, I.; Vogel, U.; Kesten, S.; Tashkin, D. P. Cardiovascular safety of tiotropium in patients with COPD Chest 2010, 137, 20-30
117. McGarvey, L. P.; Magder, S.; Burkhart, D.; Kesten, S.; Liu, D.; Manuel, R. C.; Niewoehner, D. E. Cause-specific mortality adjudication in the UPLIFT COPD trial: findings and recommendations Respir. Med. 2012, 106, 515-521
118. Lee, T. A.; Wilke, C.; Joo, M.; Stroupe, K. T.; Krishnan, J. A.; Schumock, G. T.; Pickard, A. S. Outcomes associated with tiotropium use in patients with chronic obstructive pulmonary disease Arch. Intern. Med. 2009, 169, 1403-1410
119. Dong, Y. H.; Lin, H. H.; Shau, W. Y.; Wu, Y. C.; Chang, C. H.; Lai, M. S. Comparative safety of inhaled medications in patients with chronic obstructive pulmonary disease: systematic review and mixed treatment comparison meta-analysis of randomised controlled trials Thorax 2013, 68, 48-56
120. Singh, S.; Loke, Y. K.; Enright, P. L.; Furberg, C. D. Mortality associated with tiotropium mist inhaler in patients with chronic obstructive pulmonary disease: systematic review and meta-analysis of randomised controlled trials BMJ 2011, 342, d3215
121. Wise, R. A.; Anzueto, A.; Cotton, D.; Dahl, R.; Devins, T.; Disse, B.; Dusser, D.; Joseph, E.; Kattenbeck, S.; Koenen-Bergmann, M.; Pledger, G.; Calverley, P.; TIOSPIR Investigators. Tiotropium Respimat inhaler and the risk of death in COPD N. Engl. J. Med. 2013, 369, 1491-1501
122. Loke, Y. K.; Singh, S.; Furberg, C. D. Tiotropium and the risk of death in COPD N. Engl. J. Med. 2014, 370, 480-481
123. Kesten, S.; Jara, M.; Wentworth, C.; Lanes, S. Pooled clinical trial analysis of tiotropium safety Chest 2006, 130, 1695-1703
124. Rennard, S. I.; Anderson, W.; ZuWallack, R.; Broughton, J.; Bailey, W.; Friedman, M.; Wisniewski, M.; Rickard, K. Use of a long-acting inhaled beta2-adrenergic agonist, salmeterol xinafoate, in patients with chronic obstructive pulmonary disease Am. J. Respir. Crit. Care Med. 2001, 163, 1087-1092
125. Dahl, R.; Chung, K. F.; Buhl, R.; Magnussen, H.; Nonikov, V.; Jack, D.; Bleasdale, P.; Owen, R.; Higgins, M.; Kramer, B.; INVOLVE (INdacaterol: Value in COPD: Longer Term Validation of Efficacy and Safety) Study Investigators Efficacy of a new once-daily long-acting inhaled β2-agonist indacaterol versus twice-daily formoterol in COPD Thorax 2010, 65, 473-479
126. Feldman, G.; Siler, T.; Prasad, N.; Jack, D.; Piggott, S.; Owen, R.; Higgins, M.; Kramer, B.; INLIGHT 1 Study Group. Efficacy and safety of indacaterol 150 μg once-daily in COPD: a double-blind, randomised, 12-week study BMC Pulm. Med. 2010, 10, 11
127. Donohue, J. F.; Fogarty, C.; Lotval, J.; Mahler, D. A.; Worth, H.; Yorgancioglu, A.; Iqbal, A.; Swales, J.; Owen, R.; Higgins, M.; Kramer, B.; INHANCE Study Investigators Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium Am. J. Respir. Crit. Care Med. 2010, 182, 155-162
128. Kornmann, O.; Dahl, R.; Centanni, S.; Dogra, A.; Owen, R.; Lassen, C.; Kramer, B.; INLIGHT-2 (Indacaterol Efficacy Evaluation Using 150-μg Doses with COPD Patients) Study Investigators Once-daily indacaterol versus twice-daily salmeterol for COPD: a placebo-controlled comparison Eur. Respir. J. 2011, 37, 273-279
129. Calverley, P. M.; Boonsawat, W.; Cseke, Z.; Zhong, N.; Peterson, S.; Olsson, H. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease Eur. Respir. J. 2003, 22, 912-919
130. Calverley, P.; Pauwels, R.; Vestbo, J.; Jones, P.; Pride, N.; Gulsvik, A.; Anderson, J.; Maden, C.; TRial of Inhaled STeroids ANd long-acting β2 agonists study group Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial Lancet 2003, 361, 449-456
131. Gross, N. J.; Nelson, H. S.; Lapidus, R. J.; Dunn, L.; Lynn, L.; Rinehart, M.; Denis-Mize, K.; Formoterol Study Group. Efficacy and safety of formoterol fumarate delivered by nebulisation to COPD patients Respir. Med. 2008, 102, 189-197
132. Neder, J. A.; Fuld, J. P.; Overend, T.; Thirlwell, J.; Carter, R.; Stevenson, R.; Ward, S. A. Effects of formoterol on exercise tolerance in severely disabled patients with COPD Respir. Med. 2007, 101, 2056-2064
133. O'Donnell, D. E.; Voduc, N.; Fitzpatrick, M.; Webb, K. A. Effect of salmeterol on the ventilatory response to exercise in chronic obstructive pulmonary disease Eur. Respir. J. 2004, 24, 86-94
134. Cooper, C. B. The connection between chronic obstructive pulmonary disease symptoms and hyperinflation and its impact on exercise and function Am. J. Med. 2006, 119, S21-S31
135. Donohue, J. F.; van Noord, J. A.; Bateman, E. D.; Langley, S. J.; Lee, A.; Witek, T. J., Jr.; Kesten, S.; Towse, L. A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol Chest 2002, 122, 47-55
136. Rodrigo, G. J.; Nannini, L. J.; Rodríguez-Roisin, R. Safety of long-acting β-agonists in stable COPD. A systematic review Chest 2008, 133, 1079-1087
137. Baker, W. L.; Baker, E. L.; Coleman, C. I. Pharmacologic treatments for chronic obstructive pulmonary disease: a mixed treatment comparison meta-analysis Pharmacotherapy 2009, 29, 891-905
138. Kliber, A.; Lynd, L. D.; Sin, D. D. The effects of long-acting bronchodilators on total mortality in patients with stable chronic obstructive pulmonary disease Respir. Res. 2010, 11, 56
139. Nannini, L. J.; Lasserson, T. J.; Poole, P. Combined corticosteroid and long-acting beta2-agonist in one inhaler versus long-acting beta2-agonists for chronic obstructive pulmonary disease Cochrane Database Syst. Rev. 2012, 9, CD006829
140. Appleton, S.; Poole, P.; Smith, B. J.; Veale, A.; Lasserson, T. J.; Chan, M. M.; Cates, C. J. Long-acting beta2-agonists or poorly reversible chronic obstructive pulmonary disease. Cochrane Libr. Published Online: 19 July 2006. DOI: 10.1002/14651858.CD001104.pub2.
141. Calverley, P. M. A.; Anderson, J. A.; Celli, B.; Ferguson, G. T.; Jenkins, C.; Jones, P. W.; Yates, J. C.; Vestbo, J.; TORCH Investigators. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease N. Eng. J. Med. 2007, 356, 775-789
142. Celli, B. R.; Thomas, N. E.; Anderson, J. A.; Ferguson, G. T.; Jenkins, C. R.; Jones, P. W.; Vestbo, J.; Knobil, K.; Yates, J. C.; Calverley, P. M. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study Am. J. Respir. Crit. Care Med. 2008, 178, 332-338
143. Nannini, L.; Cates, C. J.; Lasserson, T. J.; Poole, P. Combined corticosteroid and long-acting beta-agonist in one inhaler versus placebo for chronic obstructive pulmonary disease Cochrane Database Syst. Rev. 2007, 4, CD003794
144. Campbell, M.; Eliraz, A.; Johansson, G.; Tornling, G.; Nihlén, U.; Bengtsson, T.; Rabe, K. F. Formoterol for maintenance and as-needed treatment of chronic obstructive pulmonary disease Respir. Med. 2005, 99, 1511-1520
145. Szafranski, W.; Cukier, A.; Ramirez, A.; Menga, G.; Sansores, R.; Nahabedian, S.; Peterson, S.; Olsson, H. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease Eur. Respir. J. 2003, 21, 74-81
146. Battram, C.; Charlton, S. J.; Cuenoud, B.; Dowling, M. R.; Fairhurst, R. A.; Farr, D.; Fozard, J. R.; Leighton-Davies, J. R.; Lewis, C. A.; McEvoy, L.; Turner, R. J.; Trifilieff, A. In vitro and in vivo pharmacological characterization of 5-[(R)-2-(5,6-diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-1 H -quinolin-2-one (indacaterol), a novel inhaled beta2 adrenoceptor agonist with a 24-h duration of action J. Pharmacol. Exp. Ther. 2006, 317, 762-770
147. Hawkins, N. M.; Wang, D.; Petrie, M.; Pfeffer, M. A.; Swedberg, K.; Granger, C. B.; Yusuf, S.; Solomon, S. D.; Ostergren, J. O.; Michelson, E. L.; Pocock, S. J.; Maggioni, A. P.; McMurray, J. J. V.; CHARM Investigators and Committees. Baseline characteristics and outcomes of patients with heart failure receiving bronchodilators in the CHARM programme Eur. J. Heart Failure 2010, 12, 557-565
148. Hanrahan, J. P.; Grogan, D. R.; Baumgartner, R. A.; Wilson, A.; Cheng, H.; Zimetbaum, P. J.; Morganroth, J. Arrhythmias in patients with chronic obstructive pulmonary disease (COPD) occurrence frequency and the effect of treatment with the inhaled long-acting beta2-agonists arformoterol and salmeterol Medicine (Baltimore) 2008, 87, 319-328
149. Nelson, H. S.; Weiss, S. T.; Bleecker, E. R.; Yancey, S. W.; Dorinsky, P. M.; SMART Study Group. The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol Chest 2006, 129, 15-26
150. Vogelmeier, C.; Kardos, P.; Harari, S.; Gans, S. J.; Stenglein, S.; Thirlwell, J. Formoterol mono- and combination therapy with tiotropium in patients with COPD: a 6-month study Respir. Med. 2008, 102, 1511-1520
151. Tashkin, D. P.; Donohue, J. F.; Mahler, D. A.; Huang, H.; Goodwin, E.; Schaefer, K.; Hanrahan, J. P.; Andrews, W. T. Effects of arformoterol twice daily, tiotropium once daily and their combination in patients with COPD Respir. Med. 2009, 103, 516-524
152. Rabe, K. F.; Timmer, W.; Sagkriotis, A.; Viel, K. Comparison of a combination of tiotropium plus formoterol to salmeterol plus fluticasone in moderate COPD Chest 2008, 134, 255-262
153. Aaron, S. D.; Vandemheen, K. L.; Fergusson, D.; Maltais, F.; Bourbeau, J.; Goldstein, R.; Balter, M.; O'Donnell, D.; McIvor, A.; Sharma, S.; Bishop, G.; Anthony, J.; Cowie, R.; Field, S.; Hirsch, A.; Hernandez, P.; Rivington, R.; Road, J.; Hoffstein, V.; Hodder, R.; Marciniuk, D.; McCormack, D.; Fox, G.; Cox, G.; Prins, H. B.; Ford, G.; Bleskie, D.; Doucette, S.; Mayers, I.; Chapman, K.; Zamel, N.; FitzGerald, M.; Canadian Thoracic Society/Canadian Respiratory Clinical Research Consortium. Tiotropium in combination with placebo, salmeterol or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial Ann. Intern. Med. 2007, 146, 545-555
154. Singh, D.; Brooks, J.; Hagan, G.; Cahn, A.; O'Connor, B. J. Superiority of "triple" therapy with salmeterol/fluticasone propionate and tiotropium bromide versus individual components in moderate to severe COPD Thorax 2008, 63, 592-598
155. Welte, T.; Miravitlles, M.; Hernandez, P.; Eriksson, G.; Peterson, S.; Polanowski, T.; Kessler, R. Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease Am. J. Respir. Crit. Care Med. 2009, 180, 741-750
156. Salmon, M.; Luttmann, M. A.; Foley, J. J.; Buckley, P. T.; Schmidt, D. B.; Burman, M.; Webb, E. F.; DeHaas, C. J.; Kotzer, C. J.; Barrett, V. J.; Slack, R. J.; Sarau, H. M.; Palovich, M. R.; Lainé, D. I.; Hay, D. W.; Rumsey, W. L. Pharmacological characterization of GSK573719 (umeclidinium): a novel, long-acting, inhaled antagonist of the muscarinic cholinergic receptors for treatment of pulmonary diseases J. Pharmacol. Exp. Ther. 2013, 345, 260-270
157. Donohue, J. F.; Anzueto, A.; Brooks, J.; Mehta, R.; Kalberg, C.; Crater, G. A randomized, double-blind dose-ranging study of the novel LAMA GSK573719 in patients with COPD Respir. Med. 2012, 106, 970-979
158. Decramer, M.; Maltais, F.; Feldman, G.; Brooks, J.; Harris, S.; Mehta, R.; Crater, G. Bronchodilation of umeclidinium, a new long-acting muscarinic antagonist, in COPD patients Respir. Physiol. Neurobiol. 2013, 185, 393-409
159. Tal-Singer, R.; Cahn, A.; Mehta, R.; Preece, A.; Crater, G.; Kelleher, D.; Pouliquen, I. J. Initial assessment of single and repeat doses of inhaled umeclidinium in patients with chronic obstructive pulmonary disease: two randomised studies Eur. J. Pharmacol. 2013, 701, 40-48
160. Bouyssou, T.; Casarosa, P.; Naline, E.; Pestel, S.; Konetzki, I.; Devillier, P.; Schnapp, A. Pharmacological characterization of olodaterol, a novel inhaled beta2-adrenoceptor agonist exerting a 24-hour-long duration of action in preclinical models J. Pharmacol. Exp. Ther. 2010, 334, 53-62
161. Lamyel, F.; Warnken-Uhlich, M.; Seemann, W. K.; Mohr, K.; Kostenis, E.; Ahmedat, A. S.; Smit, M.; Gosens, R.; Meurs, H.; Miller-Larsson, A.; Racké, K. The beta2-subtype of adrenoceptors mediates inhibition of pro-fibrotic events in human lung fibroblasts Naunyn-Schmiedeberg's Arch. Pharmacol. 2011, 384, 133-145
162. Casarosa, P.; Kollak, I.; Kiechle, T.; Ostermann, A.; Schnapp, A.; Kiesling, R.; Pieper, M.; Sieger, P.; Gantner, F. Functional and biochemical rationales for the 24-hour-long duration of action of olodaterol J. Pharmacol. Exp. Ther. 2011, 337, 600-609
163. Aparici, M.; Gómez-Angelats, M.; Vilella, D.; Otal, R.; Carcasona, C.; Viñals, M.; Ramos, I.; Gavaldà, A.; De Alba, J.; Gras, J.; Cortijo, J.; Morcillo, E.; Puig, C.; Ryder, H.; Beleta, J.; Miralpeix, M. Pharmacological characterization of abediterol, a novel inhaled β2-adrenoceptor agonist with long duration of action and a favorable safety profile in preclinical models J. Pharmacol. Exp. Ther. 2012, 342, 497-509
164. Timmer, W.; Massana, E.; Jimenez, E.; Seoane, B.; de Miquel, G.; Ruiz, S. First-in-human study of the safety, tolerability, pharmacokinetics and pharmacodynamics of abediterol (LAS100977), a novel long-acting β2-agonist J. Clin. Pharmacol. 2014, 54, 1347-1353
165. Capacchi, S.; Lipreri, M.; Rizzi, A.; Caló, C.; Peveri, T.; Catinella, S. 1H NMR discrimination of CHF4226.01 diastereoisomers in DMSO-d6 Magn. Reson. Chem. 2009, 47, 551-561
166. Frampton, J. E. QVA149 (indacaterol/glycopyrronium fixed-dose combination): a review of its use in patients with chronic obstructive pulmonary disease Drugs 2014, 74, 465-488
167. Bateman, E. D.; Ferguson, G. T.; Barnes, N.; Gallagher, N.; Green, Y.; Henley, M.; Banerji, D. Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study Eur. Respir. J. 2013, 42, 1484-1494
168. Mahler, D. A.; Decramer, M.; D'Urzo, A.; Worth, H.; White, T.; Alagappan, V. K.; Chen, H.; Gallagher, N.; Kulich, K.; Banerji, D. Dual bronchodilation with QVA149 reduces patient-reported dyspnoea in COPD: BLAZE study Eur. Respir. J. 2014, 43, 1599-1609
169. Dahl, R.; Chapman, K. R.; Rudolf, M.; Mehta, R.; Kho, P.; Alagappan, V. K.; Chen, H.; Banerji, D. Safety and efficacy of dual bronchodilation with QVA149 in COPD patients: the ENLIGHTEN study Respir. Med. 2013, 107, 1558-1567
170. Beeh, K. M.; Korn, S.; Beier, J.; Jadayel, D.; Henley, M.; D'Andrea, P.; Banerji, D. Effect of QVA149 on lung volumes and exercise tolerance in COPD patients: the BRIGHT study Respir. Med. 2014, 108, 584-592
171. Wedzicha, J. A.; Decramer, M.; Ficker, J. H.; Niewoehner, D. E.; Sandström, T.; Taylor, A. F.; D'Andrea, P.; Arrasate, C.; Chen, H.; Banerji, D. Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study Lancet Respir. Med. 2013, 1, 199-209
172. Dahl, R.; Jadayel, D.; Alagappan, V. K.; Chen, H.; Banerji, D. Efficacy and safety of QVA149 compared to the concurrent administration of its monocomponents indacaterol and glycopyrronium: the BEACON study Int. J. Chronic Obstruct. Pulm. Dis. 2013, 8, 501-508
173. Rodrigo, G. J.; Plaza, V. Efficacy and safey of fixed-dose combination of indacaterol and glycopyrronium for the treatment of COPD: a systematic review Chest 2014, 146, 309-317
174. Rodrigo, G. J.; Plaza, V.; Castro-Rodríguez, J. A. Comparison of three combined pharmacological approaches with tiotropium monotherapy in stable moderate to severe COPD: a systematic review Pulm. Pharmacol. Ther. 2012, 25, 40-47
175. Vogelmeier, C. F.; Bateman, E. D.; Pallante, J.; Alagappan, V. K.; D'Andrea, P.; Chen, H.; Banerji, D. Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol-fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group study Lancet Respir. Med. 2013, 1, 51-60
176. Donohue, J. F.; Maleki-Yazdi, M. R.; Kilbride, S.; Mehta, R.; Kalberg, C.; Church, A. Efficacy and safety of once-daily umeclidinium/vilanterol 62.5/25 mcg in COPD Respir. Med. 2013, 107, 1538-1546
177. Celli, B.; Crater, G.; Kilbride, S.; Mehta, R.; Tabberer, M.; Kalberg, C. J.; Church, A. Once-daily umeclidinium/vilanterol 125/25 mcg in COPD: a randomized, controlled study. Chest [Online early access]. DOI: 10.1378/chest.13-1579. Published Online: Jan 2, 2014.
178. Decramer, M.; Anzueto, A.; Kerwin, E.; Kaelin, T.; Richard, N.; Crater, G.; Tabberer, M.; Harris, S.; Church, A. Efficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multicentre, blinded, randomised controlled trials Lancet Respir. Med. 2014, 2, 472-486
179. Hegde, S. S.; Hughes, A. D.; Chen, Y.; Steinfeld, T.; Jasper, J. R.; Lee, T. W.; McNamara, A.; Martin, W. J.; Pulido-Rios, M. T.; Mammen, M. Pharmacological characterization of GSK-961081 (TD-5959), a first-in-class inhaled bifunctional bronchodilator possessing muscarinic receptor antagonist and β2 adrenoceptor agonist properties J. Pharmacol. Exp. Ther. 2014, 351, 190-199
180. Bateman, E. D.; Kornmann, O.; Ambery, C.; Norris, V. Pharmacodynamics of GSK961081, a bi-functional molecule, in patients with COPD Pulm. Pharmacol. Ther. 2013, 26, 581-587
181. Anoro Ellipta FDA prescribing information, 2014. http://www.rxlist.com/anoro-ellipta-drug.htm.